Navigation Links
Fred Hutchinson Cancer Research Center opens HIV-vaccine lab in South Africa
Date:10/23/2013

SEATTLE Fred Hutchinson Cancer Research Center tomorrow will celebrate the grand opening of a state-of-the-art HIV vaccine laboratory in Cape Town,

South Africa. The lab will be one of Africa's most advanced scientific facilities.

The lab is part of the HIV Vaccine Trials Network, which is headquartered at Fred Hutch in Seattle and is the world's largest network dedicated to testing vaccine candidates for the prevention of HIV. The opening of the Cape Town HVTN Immunology Laboratory illustrates how the Hutch is constantly seeding new, international collaborations that bring researchers together to find a vaccine to end HIV.

The lab will analyze results from upcoming trials of innovative new HIV vaccines and will help African scientists advance their own research. The trials will test new and improved versions of vaccines which, in a trial conducted in Thailand, were shown to reduce the rate of HIV infection by about 30 percent the most promising HIV-vaccine results to date.

"We wanted to test the vaccines in a place where they could have the biggest benefit, and we needed the infrastructure to do that without shipping samples all the way back to Seattle," said HVTN Laboratory Center Director Julie McElrath, M.D., Ph.D., senior vice president and director of the Vaccine and Infectious Disease Division at Fred Hutch.

HVTN staff members have spent the past two years fanning out across southern Africa, scouting trial sites and laying the foundation for trials that will involve about two dozen new sites and several thousand patients. Phase 1 studies are already taking place to make sure the vaccines are safe. The goal is to launch a large phase 3 trial to confirm effectiveness and determine any side effects in 2015.

The lab will analyze blood samples from trial participants to see how their immune systems react to the vaccine and interact with the virus. If the trial confirms the Thai trial's results, researchers may learn which responses future vaccines should aim to produce. That would position scientists to launch smaller, more targeted trials that try to quickly zero in on an effective vaccine.

"If we get the right results, we could potentially make the vaccine far more effective in a relatively short period of time," said Larry Corey, M.D., Fred Hutch's president and director and HVTN principal investigator. Corey launched HVTN in 1999.

The Cape Town HVTN Immunology Laboratory received critical funding from the Bill & Melinda Gates Foundation and represents a partnership between Fred Hutch and South Africa's research community.

The lab will collaborate with local researchers and aim to increase the country's scientific capacity in the fight against HIV, said Erica Andersen-Nissen, director of the lab.

"That's a really important goal to partner with African scientists and clinicians to lay a foundation for research that extends beyond the HVTN," she said.


'/>"/>

Contact: Kristen Woodward
media@fredhutch.org
206-667-2210
Fred Hutchinson Cancer Research Center
Source:Eurekalert  

Related medicine news :

1. Hutchinson Center president elected to American Academy of Art and Sciences
2. Mount Sinai finds value and limitations of patient assistance programs for women with breast cancer
3. Like a Celebrity Concierge Brings Fun to the Fight with #ShopForACure Breast Cancer Charity Shopping Soiree at Copia NYC
4. Mount Sinai Researchers Find Value -- and Limitations -- of Patient Assistance Programs for Women with Breast Cancer
5. Airelle Skin Participates in Long Island Breast Cancer Awareness Event
6. Internet users more likely to engage in cancer-preventive behaviors
7. Study Examines Connections Between Depression and Breast Cancer, Allsup Reports
8. Rapid method to detect BRAF mutations in cancer tissue samples
9. Investigational PARP inhibitor promising in BRCA-related cancers
10. New program makes prostate cancer treatment decisions easier
11. Coffee consumption reduces risk of liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fred Hutchinson Cancer Research Center opens HIV-vaccine lab in South Africa
(Date:8/16/2017)... ... 2017 , ... Ten outstanding teachers in the Greater Houston area will be ... a visit by a Houston Texans player, two tickets to a Texans game, and ... can visit texanschecking.com/stars to nominate their favorite teacher with an essay of no more ...
(Date:8/16/2017)... ATLANTA, Georgia (PRWEB) , ... August 16, 2017 ... ... practice in Atlanta, opened their doors. They celebrate 30 years in business this ... to create an up-to-date, inviting, tranquil space to serve their patients. , ...
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced ... draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization ... out of a needle stick and more importantly, helps our staff members locate a ...
(Date:8/16/2017)... ... ... A global leader in the treatment of clubfoot, CURE International India ... the country one step closer to eliminating clubfoot as a lifelong disability by 2030. ... to enroll 10,000 children in the clubfoot treatment program in this year alone. , ...
(Date:8/16/2017)... Georgia (PRWEB) , ... August 16, 2017 , ... Fusion ... distribute premium original programming over four countries and millions of viewers in a partnership ... to rent or buy On-Demand and fully available on Blu Ray disc in 2018. ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics , ... Dallas, Texas , has received notice from the ... Institutes of Health (NIH) that it has been awarded ... totaling over $650,000 in 2017 with an additional $1,000,000 ... Investigational New Drug application of their lead non-opioid drug ...
(Date:7/31/2017)... MEMPHIS, Tenn. , July 31, 2017 Three Tru-D ... in Yongsan, South Korea . Tru-D, short for "Total ... patient and operating rooms after an environmental services (ES) professional cleans the ... ... "Although ...
(Date:7/28/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results ... and updated its financial outlook for fiscal 2017. ... third quarter, Hill-Rom reported earnings of $0.09 per diluted ... prior-year period. These results reflect after-tax special items, including ... to the non-cash write-down of assets associated with the ...
Breaking Medicine Technology: